🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Germany / NCT07420153
Recruiting Not applicable

Remote Ischemic Preconditioning and Postoperative Neuronal Injury

NCT07420153 · tracked via the Priya Life Science Germany tracker
Sponsor
University of Hamburg-Eppendorf
Phase
Not applicable
Started
2026-03-02
Last updated
2026-03-04

Condition(s) studied

Postoperative Neuronal Injury

Investigational drug(s) / intervention(s)

Remote ischemic preconditioningRoutine care

Remote ischemic preconditioning: In patients assigned to the RIPC group, we will perform RIPC on the day before surgery.

Routine care: Patients assigned to the No-RIPC group will receive routine care and RIPC will not be performed.

Study summary

The SHIELD trial is a single-center, randomized, controlled, parallel-group, single-blinded clinical trial investigating whether performing RIPC one day before surgery-compared to not performing RIPC-reduces postoperative neuronal injury, as reflected by the maximum serum NfL concentration within the first 2 postoperative days, in non-cardiac surgery patients at risk for postoperative delirium.

Eligibility

Sex
ALL
Min age
50 Years
Max age
—
Healthy volunteers
No
Inclusion criteria: * patients (≥50 years) scheduled for elective non-cardiac surgery with general anesthesia * patients at risk for postoperative delirium, defined as the presence of ≥2 of the following established risk factors: age ≥65 years, American Society of Anesthesiologists physical status classification of ≥III, Charlson Comorbidity, planned surgical duration \>180 minutes, polypharmacy (regular intake of more than five medications), symptoms of depression (Patient Health Questionnaire-9 ≥10 points) Exclusion criteria: * patients in whom RIPC cannot be safely applied due to relevant peripheral arterial disease (defined as Fontaine stage ≥II), lymphedema, recent upper-arm surgery, trauma, or skin lesions at the arm * patients with acute coronary syndrome (within the past month) * patients with surgery in the previous month * patients with intracranial surgery * patients with pre-existing delirium * patients with severe cognitive impairment preventing reliable delirium assessment * patients with current treatment with sulfonamides due to potential interference with ischemic preconditioning mechanisms * patients with previous participation in the SHIELD trial

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
University Medical Center Hamburg-Eppendorf Hamburg Free and Hanseatic City of Hamburg Recruiting

More University of Hamburg-Eppendorf trials in Germany

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07420153 on ClinicalTrials.gov ↗ ← All trials in Germany